uniQure (QURE) has drawn fresh attention after a strong rebound in its share price over the past month and past 3 months, prompting investors to reassess the gene therapy company’s risk and return trade off.

Over the past year, uniQure’s 182.47% total shareholder return and 285.92% three year total shareholder return contrast with a recent 3.59% one day share price decline. This suggests strong longer term momentum alongside short term volatility as investors reassess the company’s risk profile.

If you are weighing uniQure alongside other high growth stories, it may be a good time to scan the market for similar opportunities using the 40 healthcare AI stocks.

After uniQure’s sharp move and with the stock trading well below the average analyst target and modeled fair value range, the key question now is where fair value lies within that spread.

Most Popular Narrative: 36.2% Undervalued

Against the last close of $41.10, the most followed uniQure narrative anchors fair value at $64.47, putting a wide gap between market price and modeled potential.

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition. Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.

Want to see what is baked into that valuation gap? The narrative leans on rapid revenue expansion, rising margins and a rich future earnings multiple. The exact mix may surprise you.

Result: Fair Value of $64.47 (UNDERVALUED)

However, the uniQure story still hinges on AMT-130 clearing key regulatory milestones, and any further revenue pressure or manufacturing hiccups could quickly challenge this upbeat narrative.

Another View: uniQure’s Valuation Looks Very Rich On P/B

While our DCF model points to uniQure trading well below estimated fair value, the picture changes when you look at the P/B ratio. At 18.9x, the stock sits far above the US Biotechs industry on 2.7x and the peer average of 5.1x, which suggests valuation risk if sentiment cools.

For a closer look at what this gap could mean in practice, including how the ratio might move toward a fair ratio over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With such mixed signals around uniQure, it helps to look past the headlines and weigh the trade off between concern and optimism for yourself. To see how the balance of 1 or more risks and 1 or more rewards stacks up, review the 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond uniQure?

If uniQure has sharpened your focus, do not stop here. Widen your watchlist now or you may risk missing opportunities that better match your goals.

• Target higher quality potential by scanning companies that look cheap on fundamentals using the 46 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks screened for resilient payouts through the 8 dividend fortresses.
• Prioritize resilience by focusing on companies flagged for robust financial footing in the solid balance sheet and fundamentals stocks screener (47 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.